Related Experiment Video
Updated: Oct 9, 2025
Examining BCL-2 Family Function with Large Unilamellar Vesicles
Published on: October 5, 2012
Expression Differences in BCL2 Family Members between Uveal and Cutaneous Melanomas Account for Varying Sensitivity
Nabanita Mukherjee1, Chiara R Dart2, Carol M Amato3
1Department of Dermatology, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Abstract:
Uveal melanoma (UM) is a subtype of melanoma. Although they share a melanocytic origin with cutaneous melanoma (CM), patients with UM have few treatment options. BCL2 homologous 3 mimetics are small-molecule drugs that mimic proapoptotic BCL2 family members. We compared BCL2 family member expression between UM and CM using immunoblot and The Cancer Genome Atlas transcriptomic analysis. UM has a unique signature of low BFL1 and high PUMA proteins compared with CM and 30 other cancer types, making them an attractive candidate for BCL2 homologous 3 protein mimetics. We tested the efficacy of a BCL2 inhibitor and MCL1 inhibitor (MCL1i) in UM, with viability assays, live-cell imaging, sphere assays, and mouse xenograft models. UM had a higher sensitivity to MCL1i than CM. Overexpression of BFL1 or knockdown of PUMA made the UM more resistant to MCL1i. In contrast, MAPK/extracellular signal‒regulated kinase inhibitor treatment in CM made them more sensitive to MCL1i. However, MCL1i-alone treatment was not very effective to reduce the UM initiating cells; to overcome this, we employed a combination of MCL1i with BCL2 inhibitor that synergistically inhibited UM initiating cell's capacity to expand. Overall, we identify a distinct expression profile of BCL2 family members for UM that makes them susceptible to BCL2 homologous 3 mimetics.
Insights
Uveal melanoma (UM) exhibits a unique BCL2 family protein profile, making it susceptible to BCL2-targeting drugs. Combination therapy with MCL1 and BCL2 inhibitors shows promise for treating UM initiating cells.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Uveal melanoma (UM) is a rare eye cancer with limited treatment options.
- BCL2 homologous 3 (BH3) mimetics are drugs that target pro-apoptotic BCL2 family proteins.
- Understanding BCL2 family expression in UM is crucial for developing targeted therapies.
Purpose of the Study:
- To compare BCL2 family member expression in UM versus cutaneous melanoma (CM).
- To evaluate the efficacy of BCL2 and MCL1 inhibitors in UM.
- To identify effective therapeutic strategies for UM initiating cells.
Main Methods:
- Immunoblotting and The Cancer Genome Atlas (TCGA) transcriptomic analysis.
- Viability assays, live-cell imaging, sphere assays, and mouse xenograft models.
- Testing of BCL2 inhibitor, MCL1 inhibitor (MCL1i), and combination therapies.
Main Results:
- UM shows a unique BCL2 family signature: low BFL1 and high PUMA.
- UM is more sensitive to MCL1i than CM.
- Combination of MCL1i and BCL2 inhibitor synergistically inhibited UM initiating cell expansion.
Conclusions:
- UM has a distinct BCL2 family expression profile making it a candidate for BH3 mimetics.
- Targeting MCL1 and BCL2 concurrently is a promising strategy for UM treatment.
- This study identifies a novel therapeutic approach for uveal melanoma.
Related Concept Videos
01:31The Intrinsic Apoptotic Pathway
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:30Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...